The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Open accessAbstract
The complexity of cancer has led to recent interest in polypharmacological approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict. Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here we identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity. Drosophila genetics and compound profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity. Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the ‘anti-target’ Tor led to toxicity owing to release of negative feedback. Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compounds featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models. Combining kinase-focused chemistry, kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacology approach towards developing compounds with a maximal therapeutic index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Network motifs: theory and experimental approaches
Alon, U. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2102 · Cited by 3,279
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“Kinase-signalling pathways are often involved in pathogenesis, and kinase mutations are common and potent drivers of oncogenesis 1–4 .”
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“By contrast, most drugs approved for clinical use have multiple targets 11–13 .”
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
Hinz, U., Giebel, B., & Campos-Ortega, J. (1994) · Cell · doi:10.1016/0092-8674(94)90174-0 · Cited by 301
LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
Mestres, J., Gregori-Puigjané, E., Valverde, S., & Solé, R. V. (2009) · Molecular BioSystems · doi:10.1039/b905821b · Cited by 203
Vidal, M., Larson, D. E., & Cagan, R. L. (2006) · Developmental Cell · doi:10.1016/j.devcel.2005.11.007 · Cited by 173
Self-citationGuichard, A., Biehs, B., Sturtevant, M. A., Wickline, L., Chacko, J., Howard, K., & Bier, E. (1999) · Development · doi:10.1242/dev.126.12.2663 · Cited by 156
Vidal, M., Wells, S. A., Ryan, A. J., & Cagan, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4561 · Cited by 154
Self-citationGedaly, R., Angulo, P., Hundley, J. C., Daily, M. F., Chen, C., Koch, A., & Evers, B. M. (2010) · PubMed · Cited by 143
The Drosophila Bcl-2 family member dBorg-1 functions in the apoptotic response to UV-irradiation
Brachmann, C. B., Jassim, O. W., Wachsmuth, B. D., & Cagan, R. L. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00474-7 · Cited by 126
Self-citationClinical Experience with Aurora Kinase Inhibitors: A Review
Boss, D. S., Beijnen, J. H., & Schellens, J. H. M. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0019 · Cited by 107
Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation
Dar, A. C., Lopez, M. S., & Shokat, K. M. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.007 · Cited by 105
Self-citationRead, R. D., Bach, E. A., & Cagan, R. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6676-6689.2004 · Cited by 96
Self-citationA Drosophila Model of Multiple Endocrine Neoplasia Type 2
Read, R. D., Goodfellow, P. J., Mardis, E. R., Novak, N., Armstrong, J. R., & Cagan, R. L. (2005) · Genetics · doi:10.1534/genetics.104.038018 · Cited by 94
Self-citationSolid tumors associated with multiple endocrine neoplasias
Almeida, M. Q., & Stratakis, C. A. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.09.006 · Cited by 66
Differing Src Signaling Levels Have Distinct Outcomes in Drosophila
Vidal, M., Warner, S., Read, R. D., & Cagan, R. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1376 · Cited by 65
Self-citation
Cited by
Gasque, G., Conway, S., Huang, J., Rao, Y., & Vosshall, L. B. (2013) · Scientific Reports · doi:10.1038/srep02120 · Cited by 2,292
Roth, B. L. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.040 · Cited by 1,742
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Metadata
- Authors
- Dar, A. C., Das, T. K., Shokat, K. M., & Cagan, R. L.
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7401
- Pages
- 80-84
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1972577475
- Cited by
- 333
- References
- 33
- FWCI
- 24.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.